## SUPPLEMENTARY MATERIAL

## Network mata-analysis

**Study selection and data extraction of network meta-analysis:** To fully assess the clinical benefit of different regimens in patients with advanced hepatocellular carcinoma (HCC), we conducted a meta-analysis including relevant randomized clinical trials (RCTs), which certified that , and that combination therapies were superior to monotherapies, in compliance with the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and reported results based on Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) reporting guideline.

An extensive literature search was performed from PubMed, Embase and the Cochrane Central Register of Controlled Trials databases for RCTs published in English from January 1, 2018, to January 1, 2023. We searched the abstracts of ESMO and ASCO from 2020 to 2022 as well. Data analysis began in January 2023. A combined search strategy of medical subject headings plus free-text terms was adopted to identify relevant studies. The full search strategy was detailed below: (1) research objective: history of HCC; (2) randomized-controlled studies with head-to-head comparisons of at least two treatment arms, and similar articles published by the same author recently; (3) systemic firstline therapy for unresectable, progressing or advanced HCC; (4) outcome indicators were OS or ORR per RECIST1.1 that could be obtained from the original article or supplementary materials; (5)reports of phase III RCTs certifying the monotherapies were not inferior to Sorafenib or other proven non-inferiority regimens such as Lenvatinib and HAIC in the first-line treatment of patients with advanced HCC or additional benefit of combination therapies versus monotherapies in the first-line treatment of patients with advanced HCC; and (6) not study on adjuvant or neoadjuvant therapy. If multiple publications of the same study were retrieved, the most recent and informative publication was selected. Phase I, phase II, dose-finding, adjuvant and neoadjuvant, second or later-line setting trials were excluded. News, editorials, letters, commentaries, retrospective studies, review articles were also excluded. Two authors (Yu-Zhe Cao and Meng-Xuan Zuo) independently screened the trials for eligibility and extracted the following information from each trial: trial name, year of publication, sample size, treatment regimens in both arms and results of statistical testing of primary endpoints. Any discrepancies were resolved by consensus. The included RCTs were additionally assessed for risk of bias using the Cochrane Risk of bias (RoB 2) tool, which yielded low risk for all studies included (Supplementary Figure 1).

Although LEAP-002 study did not meet its superiority threshold, the study demonstrated Pembrolizumab combined with Lenvatinib could prolong overall survival compared with Lenvatinib alone for the patients with advanced HCC (21.2 months *vs* 19.0 months, HR = 0.840, Cl 0.708-0.997, P = 0.0227). So we still brought LEAP-002 study into network meta-analysis. However, the analysis only included the phase III RCT superior to sorafenib or lenvatinib published in the English, which may caused bias and limits the reliability of the analysis.

## Search strategy

(1) PubMed

#1 controlled clinical trial [pt]
#2 randomized controlled trial [pt]
#3 randomized [tiab]
#4 randomly [tiab]
#5 trial\* [tiab]
#6 rct [tiab]

#7 clinical trials [mh]

#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7

#9 hepatocellular carcinoma [tiab]

#10 liver cancer [tiab]

#11 HCC [tiab]

#12 #9 OR #10 OR #11

#13 #8 AND #12

#14 advanced[tiab]

#15 unresectable[tiab]

#16 progressing[taib]

#17 #14 OR #15 OR #16

#18 #13 AND #17

#19 #English[la]

#20 #18 AND #19

#21animals [mh] NOT humans [mh]

#22 #20 NOT #21

((RCT[Title/Abstract]) OR (randomized controlled trial[Title/Abstract]) OR (controlled clinical tria[Title/Abstract]]) OR (clinical trials[Title/Abstract]) OR (trial\*[Title/Abstract]) OR (clinical trials[MeSH Terms])) AND ((hepatocellular carcinoma[Title/Abstract]) OR (HCC[Title/Abstract]) OR (liver cancer[Title/Abstract])) AND ((advanced[Title/Abstract]) OR OR (progressing[Title/Abstract])) (unresectable[Title/Abstract]) AND (English[Language]) NOT ((animals[MeSH Terms]) NOT (humans[MeSH Terms]))

(2) Embase (Ovid)

#1 'liver cell carcinoma':ab,ti OR 'liver cell cancer':ab,ti OR 'hepatocellular carcinoma':ab,ti OR hcc:ab,ti

#2 'advanced' OR 'unresectable' OR 'progressing'

#3 'randomized controlled trial':de OR 'clinical study'

#4 'human' NOT 'animal'

#5 'phase 3 clinical trial'/de

#6 #1 AND #2 AND #3 AND #4

(3) Cochrane Central Register of Controlled Trials

#1 ('hepatocellular carcinoma' OR 'liver cancer' OR hcc):ti,ab,kw


#2 ('progressing' OR 'advanced' OR 'unresectable'):ti,ab,kw

#3 English:la

#4 ("RCT" OR "controlled clinical trial" OR "randomized controlled trial" OR "clinical trials"):ti,ab,kw

#5 #1 AND #2 AND #3 AND #4


## **Supplementary Figures**




Supplementary Figure 1 Preferred reporting items for systematic reviews and meta-analyses flowchart of included studies.

ID	<u>Experimental</u>	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	<u>0veral1</u>		
1	REFLECT, 2018	+	+	+	+	+	+	+	Low risk
2	FOHAIC1, 2022	+	+	+	+	+	+	!	Some concerns
3	SoraHAIC, 2021	+	+	+	+	+	+	•	High risk
4	IMBrave150, 2022	+	+	+	+	+	+		
5	SHR1310III310, 2022	+	+	+	+	+	+	D1	Randomisation pr
6	LEAP002, 2022	+	+	+	+	+	+	D2	Deviations from
7	ORIENT32, 2021	+	+	+	+	+	+	D3	Missing outcome
8	CheckMate 459, 2021	+	+	+	+	+	+	D4	Measurement of t
9	SIRveNIB, 2019	+	+	•	+	+	+	D5	Selection of the
10	LAUNCH, 2022	+	+	•	+	+	+		
11	TACTICS, 2022	+	+	+	+	+	+		
12	ZGDH3, 2021	+	+	+	+	+	+		
13	HIMALAYA1, 2022	+	+	+	+	+	+		
14	RATIONALE301, 2022	+	+	+	+	+	+		


Supplementary Figure 2 Risk of bias of researches.




Supplementary Figure 3 Forest plot on odds ratios for objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 compared to sorafenib in the form of odds ratio.



Supplementary Figure 4 Forest plot on hazrd ratios for overall survival compared to sorafenib in the form of hazard ratio.



Supplementary Figure 5 Patients' selection flow.



Supplementary Figure 6 Kaplan-Meier curves of overall survival in the triple therapy groups between different populations. A: the patients with HAIC 10 / 23

rounds more than 4 or not, not reached *vs* 18.2 mo; P < 0.001; B: the patients with single or multiple tumors, not reached *vs* 24.6 months; P < 0.001.

ID	Study	Yr	Arm	Patients number	Mal	Age	ECOG	-	Child-P	BCLC		EH
	-			, n	e	-	PS > 0	is virus	ugh A	C	Ι	Μ
1	REFLEC	2018	Lenvatinib	478	85	63 (20-88) <sup>1</sup>	100	72	99	78	23	61
1	Т	2010	Sorafenib	476	84	62 (22-88) <sup>1</sup>	100	74	99	81	19	62
2	FOHAI	2022	HAIC	130	89	54 (45-61) <sup>2</sup>	74	94	68	96	72	34
2	С	2022	Sorafenib	132	93	53 (45-62) <sup>2</sup>	82	89	71	93	69	35
	SoraHA		HAIC +	125	89	49 (41-55) <sup>2</sup>	73	85	100	100	100	30
3	IC	2021	Sorafenib	125	69	49 (41-55)-	75	85	100	100	100	30
	IC.		Sorafenib	122	92	49 (40-56) <sup>2</sup>	75	87	100	100	100	34
			Atezolizuma									
4	IMBrav	2020	b +	336	82	64 (56-71) <sup>2</sup>	100	70	100	82	38	63
4	e150	2020	Bevacizumab									
			Sorafenib	165	83	66 (59 <b>-</b> 71) <sup>2</sup>	100	68	100	81	43	56
	SHR131		Camrelizuma									
5		2022	b +	272	83	58 (48-66) <sup>2</sup>	100	85	87	86	15	64
	0III310		Rivoceranib									

Supplementary Table 1 Baseline demographics of participants in included studies (%)

			Sorafenib	271	85	56 (47-64) <sup>2</sup>	100	83	85	85	19	66
			Lenvatinib +									
(	LEAP00	2022	Pembrolizum	395	80	66 (19-88) <sup>1</sup>	100	62	99	78	18	63
6	2	2022	ab									
			Lenvatinib	399	82	66 (20-88) <sup>1</sup>	100	59	99	76	15	61
			Sintilimab +									
7	ORIEN	2021	Bevacizumab	380	88	53 (21-82) <sup>1</sup>	100	96	96	85	28	73
7	T-32	2021	biosimila									
			Sorafenib	191	90	54 (28-77) <sup>1</sup>	100	98	95	86	26	75
0	CheckM	0001	Nivolumab	371	85	65 (57-71) <sup>2</sup>	100	55	98	82	33	60
8	ate 459	2021	Sorafenib	372	85	65 (58-72) <sup>2</sup>	100	55	96	78	32	56
			CIDT	100	01	59.5 ±	100	(0)	01	40	01	0
0	SIRveNI	2010	SIRT	182	81	12.93	100	68	91	48	31	0
9	В	2019	C ( '1	170	05	57.7 ±	100	70	00	4 🗖	20	0
			Sorafenib	178	85	10.63	100	72	90	45	30	0
			TACE +	170	0 <b>7</b>	EA(AC(A))	100	20	100	100	70	FF
10	LAUNC	2022	Lenvatinib	170	82	54 (46-64) <sup>2</sup>	100	89	100	100	72	55
	Η		Lenvatinib	168	79	56 (48-63) <sup>2</sup>	100	89	100	100	70	56

11	ZGDH3	2021	Donafenib	328	86	53 (46-62) <sup>2</sup>	100	91	99	87	NA	NA
11	ZGDH3	2021	Sorafenib	331	88	53 (46-61) <sup>2</sup>	100	93	96	88	NA	NA
			Durvalumab									
			+	202	00		00	50	00	00	26	50
10	HIMAL	2022	Tremelimum	393	83	65 (22-86) <sup>1</sup>	99	59	98	80	26	53
12	AYA	2022	ab									
			Durvalumab	389	83	64 (20-86) <sup>1</sup>	99	57	98	79	24	54
			Sorafenib	389	87	64 (18-88) <sup>1</sup>	99	57	97	83	26	52
	RATIO		Tislelizumab	342	84	62 (25-86) <sup>1</sup>	100	76	99	79	15	64
13	NALE3	2022	0 ( 1	222	05		100		100	-	4 -	(0)
	01 (26)		Sorafenib	332	85	60 (23-86) <sup>1</sup>	100	76	100	76	15	60

<sup>1</sup>Ages are reported as median (range).

<sup>2</sup>Ages are reported as median (interquartile range).

 $^{3}$ Ages are reported as mean  $\pm$  SD.

BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; MVI: macrovascular invasion; EHM: extrahepatic metastasis; HAIC: hepatic arterial infusion chemotherapy; TACE: transcatheter arterial chemoembolization; SIRT: selective internal radiation therapy.

Suppr		y lable 2	League
Atezo			
lizum			
ab +			
Bevac			
izum			
ab			
	Camr		
	elizu		
0.61	mab		
(0.27,	+		
1.36)	Rivoc		
,	erani		
	b		
1.0.1			
1.94	3.2	Donaf	
(0.69,	(1.1,	enib	
5.33)	9.04)		
			-
0.88	1.45	0.46	Durv
(0.42,	(0.67,	(0.17,	alum
1.9)	3.22)	1.26)	ab

Supplementary	y Table 2 League table or	odds ratio for ob	iective per RECIST 1.1
0 0 p p - 0	,		

0.71 (0.34, 1.53)	1.18 (0.54, 2.59)	0.37 (0.14, 1)	0.81 (0.56, 1.16)	Durv alum ab + Trem elimu mab			
0.09 (0.01, 0.39)	0.15 (0.02, 0.64)	0.05 (0.01, 0.23)	0.11 (0.01, 0.42)	0.13 (0.02, 0.52)	HAIC		
0.11 (0.02, 0.38)	0.18 (0.04, 0.62)	0.06 (0.01, 0.23)	0.12 (0.03, 0.42)	0.15 (0.03 <i>,</i> 0.51)	1.17 (0.16, 10.5)	HAIC + Soraf enib	
1 (0.5, 2.07)	1.65 (0.8, 3.48)	0.51 (0.2, 1.38)	1.13 (0.58, 2.26)	1.4 (0.72, 2.8)	10.66 (2.71, 77.44)	9.25 (2.81, 43.05)	1010

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$													 	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(0.28,	(0.45,	(0.11,	(0.32,	(0.4,	(1.57,	(1.61,	(0.43,	tinib + Pemb rolizu					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(0.67,	(1.08,	(0.27,	(0.76,	(0.96,	(3.73,	(3.78,	(0.71,	(1.09,					
(0.05, (0.09, (0.02, (0.06, (0.08, (0.39, (0.38, (0.06, (0.09, (0.04, (0.1, SIRT	(0.18,	(0.28,	(0.07,	(0.2,	(0.25,	(1.11,	(1.11,	(0.18,	(0.29,	(0.13,	mab + Bevac izum ab biosi			
	(0.05,	(0.09,	(0.02,	(0.06,	(0.08,	(0.39,	(0.38,	(0.06,	(0.09,	(0.04,	(0.1,	SIRT		

3.37 (1.99, 6.01)	5.53 (3.17, 10.18)	1.73 (0.75, 4.22)	3.81 (2.29, 6.53)	4.7 (2.89, 8.05)	35.66 (9.94, 249.91 )	30.95 (10.52 , 137.25 )	3.36 (2.2, 5.31)	5.59 (3.23, 9.83)	2.44 (1.5, 4.03)	6.79 (3.25 <i>,</i> 16.74)	12.84 (4.27, 57.15)	Soraf enib		
0.31 (0.13, 0.74)	0.51 (0.21, 1.21)	0.16 (0.05, 0.47)	0.35 (0.15, 0.81)	0.43 (0.19, 0.99)	3.29 (0.76, 25.27)	2.85 (0.79, 14.44)	0.31 (0.19, 0.49)	0.51 (0.28, 0.92)	0.22 (0.1, 0.51)	0.62 (0.23, 1.86)	1.18 (0.32, 5.75)	0.09 (0.05, 0.17)	TACE + Lenva tinib	
1.14 (0.52, 2.53)	1.87 (0.83, 4.25)	0.59 (0.21, 1.65)	1.29 (0.59, 2.78)	1.59 (0.74, 3.43)	12.18 (2.92, 92.03)	10.49 (2.98, 50)	1.14 (0.55, 2.31)	1.89 (0.85, 4.13)	0.82 (0.39, 1.74)	2.3 (0.9, 6.56)	4.37 (1.24, 21.55)	0.34 (0.19, 0.58)	3.69 (1.57, 8.84)	Tisleli zuma b

HAIC: hepatic arterial infusion chemotherapy; TACE: transcatheter arterial chemoembolization.

	<i>y</i> ~	S League table on nazaru fatio foi overan survivar
Camr		
elizu		
mab		
+		
Rivoc		
erani		
b		
0.75	- (	
(0.56,		
1.02)	enib	
0.72	0.96	Durv
	Camr elizu mab + Rivoc erani b 0.75 (0.56, 1.02)	Camr elizu mab + Rivoc erani b 0.75 (0.56, Donaf (0.56, enib 1.02)

Supplementary Table 3 League table on hazard ratio for overall survival

(0.57,	(0.54,	(0.75,	alum				
1.04)	0.97)	1.22)	ab				
				Durv			
0.85	0.8	1.07	1.11	alum			
(0.63,	(0.8 (0.59 <i>,</i>	(0.83,	(0.87,	ab +			
				Trem			
1.16)	1.09)	1.37)	1.43)	elimu			
				mab			
1.63	1.54	2.04	2.13	1.91			
(1.1,	(1.04,	(1.44,	(1.5,	(1.35,	HAIC		
2.4)	2.26)	2.88)	3)	2.71)			
1.88	1.77	2.35	2.45	2.2	1.15	HAIC	
(1.27,	(1.19,	(1.66,	(1.73,	(1.54,	(0.75,	+	
2.78)	(1.1), 2.63)	(1.00, 3.34)	(1.73)	(1.54, 3.14)	(0.73)	Soraf	
2.70)	2.00)	5.54)	5.47)	5.14)	1.//)	enib	
0.73	0.68	0.91	0.95	0.85	0.45	0.39	Lenva
(0.55,	(0.51,	(0.72,	(0.76,	(0.68,	(0.32,	(0.27,	tinib
0.97)	0.91)	1.14)	1.19)	1.07)	0.62)	0.54)	uiiiD

								Lenva			
0.86	0.81	1.08	1.13	1.01	0.53	0.46	1.19	tinib			
(0.62,	(0.58,	(0.81,	(0.85,	(0.76,	(0.36,	(0.31,	(1,	+			
		•						Pemb			
1.21)	1.14)	1.43)	1.49)	1.35)	0.78)	0.67)	1.41)	rolizu			
								mab			
0.77	0.73	0.97	1.01	0.91	0.47	0.41	1.07	0.9	Nivol		
(0.57,	(0.54,	(0.76,	(0.79,	(0.71,	(0.34,	(0.29,	(0.85,	(0.67,	umab		
1.05)	0.98)	1.24)	1.29)	1.17)	0.67)	0.58)	1.34)	1.19)	umau		
										Sintili	
										mab	
1.17	1.1	1.46	1.53	1.37	0.72	0.62	1.61	1.35	1.51	+	
(0.81,	(0.76,	(1.05,	(1.1,	(0.98,	(0.48,	(0.41,	(1.17,	(0.94,	(1.09,	Bevac	
	(0.70,	(1.00)	(1.1)	(0.90,	(0.40)	(0.41)	(1.17)	(0.94 <i>)</i> 1.95)		izum	
1.7)	1.0)	2.03)	2.11)	1.91)	1.09)	0.94)	2.21)	1.95)	2.1)	ab	
										biosi	
										milar	
0.59	0.56	0.74	0.77	0.69	0.36	0.31	0.82	0.69	0.76	0.5	SIRT

(0.42,	(0.4,	(0.56,	(0.58,	(0.52,	(0.25,	(0.22,	(0.62,	(0.5,	(0.58,	(0.35,				
0.82)	0.77)	0.98)	1.02)	0.92)	0.53)	0.46)	1.06)	0.94)	1.01)	0.72)				
0.66	0.62	0.83	0.87	0.78	0.41	0.35	0.91	0.77	0.86	0.57	1.12	Soraf		
(0.52,	(0.49,	(0.7,	(0.73,	(0.65,	(0.3,	(0.26,	(0.79,	(0.61,	(0.72,	(0.43,	(0.9,	Soraf enib		
0.85)	0.8)	0.98)	1.03)	0.93)	0.55)	0.48)	1.06)	0.96)	1.02)	0.75)	1.4)	enib		
1 (1	1 50	2.02	0 11	1.00	0.00	0.97	2 22	1 07	2.00	1 20	0.72	<b>D</b> 42	TACE	
1.61	1.52	2.02	2.11	1.89	0.99	0.86	2.23	1.87	2.09	1.38	2.73	2.43	+	
(1.07,	(1,	(1.38,	(1.44,	(1.29,	(0.63,	(0.54,	(1.63,	(1.32,	(1.43,	(0.89,	(1.83,	(1.73,	Lenva	
2.46)	2.31)	2.96)	3.08)	2.77)	1.56)	1.36)	3.03)	2.66)	3.06)	2.14)	4.1)	3.42)	tinib	
0.78	0.73	0.98	1.02	0.91	0.48	0.42	1.08	0.9	1.01	0.67	1.32	1.18	0.48	Tisleli
(0.55,	(0.51,	(0.71,	(0.75,	(0.66,	(0.32,	(0.28,	(0.8,	(0.64,	(0.74,	(0.46,	(0.94,	(0.9,	(0.32,	zuma
1.11)	1.05)	1.33)	1.39)	1.24)	0.71)	0.62)	1.44)	1.27)	1.37)	0.98)	1.86)	1.52)	0.73)	b

HAIC: hepatic arterial infusion chemotherapy; TACE: transcatheter arterial chemoembolization.

	Triple therapy group $(n =$	$\mathbf{AIDB} = (n - 110)$	Triple therapy group (n =	AIPB group ( $n = 88$ )	
	324)	AIPB group ( $n = 118$ )	88)		
Response	Before PSM		After PSM		
CR	21 (6.5)	4 (3.4)	6 (6.8)	4 (4.5)	
PR	183 (56.5)	31 (26.3)	43 (48.9)	27 (30.7)	
Stable disease	79 (24.4)	55 (46.6)	24 (27.3)	34 (38.6)	
PD	41 (12.7)	28 (23.7)	15 (17.0)	23 (26.1)	
ORR	204 (62.9)	35 (29.7)	49 (55.7)	31 (35.2)	

Supplementary Table 4 Tumor response per modified Response Evaluation Criteria in Solid Tumors, n (%)

AIPB: angiogenesis inhibitors plus programmed cell death protein 1/programmed death ligand 1 blockers; PSM: propensity score matching; CR: complete response; PR: partial response; PD: programmed death; ORR: objective response rate.